Geno J. Merli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Geno J. Merli has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Howard H. Weitz
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania (H.H.W.).
12 shared publications - Taki Galanis
Division Vascular Medicine, Jefferson Vascular Center, Sidney Kimmel Medical College, Philadelphia, PA, USA
5 shared publications - Anthony Macchiavelli
Thomas Jefferson University Hospitals
3 shared publications - Brett J. Carroll
Beth Israel Deaconess Medical Center
3 shared publications Taki Galanis
Jefferson Vascular Center, Jefferson Medical College, Thomas Jefferson University Hospitals, Gibbon Building, 111 South 11th Street, Suite 6270, Philadelphia, PA, USA
3 shared publications- Adam J. Singer
Department of Emergency Medicine, Stony Brook University, Stony Brook, NY, USA
2 shared publications
Latest Publications
- 20 August 2026
- Published by Springer Nature
- p. 1-32
The Pulmonary Embolism Response Team and Hospital Relationship
- 20 August 2026
- Published by Springer Nature
- p. 1-32
The Pulmonary Embolism Response Team and Hospital Relationship
- 1 April 2026
- Published by Springer Nature
- p. 377-393
Prevention of Venous Thromboembolism
- Open Access
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e044011
Adjudicated Cardiovascular Events in Patients With COVID‐19: Association With Vaccination Status and Changes over Time
Background: Patients with COVID‐19 are at risk of thrombotic and cardiovascular complications. Existing risk estimates derive from early COVID‐19 experiences. More recent event rates, temporal trends, and the association between vaccination status and cardiovascular outcomes remain unclear. Methods: The CORONA‐VTE Network (COVID‐19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications) multicenter registry included patients with COVID‐19 from March 2020 to February 2024. A composite of venous and arterial thrombotic events and a composite of adjudicated cardiovascular events were assessed at 90 days after COVID‐19 diagnosis. Time‐to‐first‐event analyses were stratified by inpatients and outpatients and adjusted for competing risks. Outcomes were adjudicated by independent physicians. Results: Of 11 165 patients, 4451 were inpatients (mean age, 65 years; 47% women) and 462 of 4451 were admitted to the intensive care unit. Among inpatients, the 90‐day cumulative incidences of thrombotic and cardiovascular events were 8.9% (95% CI, 8.0%–9.8%) and 15.6% (95% CI, 14.5%–16.7%), respectively. Corresponding estimates for patients in the intensive care unit were 20.0% (95% CI, 16.6%–24.0%) and 30.7% (95% CI, 26.8%–35.3%), while event rates were low among outpatients. There was an initial decline in cardiovascular events (adjusted hazard ratio [HR], 0.84; P =0.001) after the first COVID‐19 wave, with a subsequent catch‐up, with no significant linear change in cardiovascular events (adjusted P trend =0.634). Vaccination was associated with a reduced risk of cardiovascular events (adjusted HR, 0.75 [95% CI, 0.62–0.92]; P =0.005). Conclusions: Thrombotic and cardiovascular events are common in hospitalized patients with COVID‐19, especially those in the intensive care unit, without a persistent decline over time. COVID‐19 vaccination was associated with a reduced risk of cardiovascular events.
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e044011
Open AccessAdjudicated Cardiovascular Events in Patients With COVID‐19: Association With Vaccination Status and Changes over Time
Background: Patients with COVID‐19 are at risk of thrombotic and cardiovascular complications. Existing risk estimates derive from early COVID‐19 experiences. More recent event rates, temporal trends, and the association between vaccination status and cardiovascular outcomes remain unclear. Methods: The CORONA‐VTE Network (COVID‐19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications) multicenter registry included patients with COVID‐19 from March 2020 to February 2024. A composite of venous and arterial thrombotic events and a composite of adjudicated cardiovascular events were assessed at 90 days after COVID‐19 diagnosis. Time‐to‐first‐event analyses were stratified by inpatients and outpatients and adjusted for competing risks. Outcomes were adjudicated by independent physicians. Results: Of 11 165 patients, 4451 were inpatients (mean age, 65 years; 47% women) and 462 of 4451 were admitted to the intensive care unit. Among inpatients, the 90‐day cumulative incidences of thrombotic and cardiovascular events were 8.9% (95% CI, 8.0%–9.8%) and 15.6% (95% CI, 14.5%–16.7%), respectively. Corresponding estimates for patients in the intensive care unit were 20.0% (95% CI, 16.6%–24.0%) and 30.7% (95% CI, 26.8%–35.3%), while event rates were low among outpatients. There was an initial decline in cardiovascular events (adjusted hazard ratio [HR], 0.84; P =0.001) after the first COVID‐19 wave, with a subsequent catch‐up, with no significant linear change in cardiovascular events (adjusted P trend =0.634). Vaccination was associated with a reduced risk of cardiovascular events (adjusted HR, 0.75 [95% CI, 0.62–0.92]; P =0.005). Conclusions: Thrombotic and cardiovascular events are common in hospitalized patients with COVID‐19, especially those in the intensive care unit, without a persistent decline over time. COVID‐19 vaccination was associated with a reduced risk of cardiovascular events.
- 15 November 2025
- Published by Springer Nature
- p. 1-19
Pharmacology of Anticoagulation
- 4 September 2025
- Published by Springer Nature
- p. 1-19
Venous Thromboembolism Prophylaxis in the Surgical Patient
- 4 September 2025
- Published by Springer Nature
- p. 1-19
Venous Thromboembolism Prophylaxis in the Surgical Patient
- 27 February 2025
- Published by Springer Nature
- p. 1-24
Venous Thromboembolism: Risk Assessment and Prophylaxis in the Medically Ill
- 27 February 2025
- Published by Springer Nature
- p. 1-24
Venous Thromboembolism: Risk Assessment and Prophylaxis in the Medically Ill
- Open Access
- 24 December 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (1) , 4
Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
The last two decades have provided far more options f both patients and their physicians in the treatment of diabetes mellitus. While dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been approved for nearly two decades, sodium–glucose cotransporter 2 inhibitors (SGLT-2is) are relatively new. Of interest to perioperative physicians, these drugs present specific perioperative concerns, prompting many societies to issue guidelines. Retained gastric contents due to slow gastric emptying is a significant drawback of GLP-1RAs, increasing the risk of aspiration. Recommendations include withholding GLP-1RAs for a predefined period of time, performing gastric ultrasound to evaluate gastric contents, modifying anesthesia management, particularly with regard to the airway, or canceling the scheduled (elective) surgery or procedure. SGLT-2is are known to increase the risk of euglycemic ketoacidosis. The benefits of both GLP-1RAs and SGLT-2is extend beyond the treatment of diabetes. As a result, perioperative physicians may encounter their use outside of their traditional indications. SGLT-2is are being used extensively to treat heart failure and obesity, for example. There have been other developments as well. For instance, Imeglimin, a variant of metformin available in Japan and India, Icodec, a once-weekly basal insulin formulation, and IcoSema, a once-weekly combination of Icodec plus semaglutide, are all being explored, although in their early stages or facing approval challenges.
- 24 December 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (1) , 4
Open AccessGlucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
The last two decades have provided far more options f both patients and their physicians in the treatment of diabetes mellitus. While dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been approved for nearly two decades, sodium–glucose cotransporter 2 inhibitors (SGLT-2is) are relatively new. Of interest to perioperative physicians, these drugs present specific perioperative concerns, prompting many societies to issue guidelines. Retained gastric contents due to slow gastric emptying is a significant drawback of GLP-1RAs, increasing the risk of aspiration. Recommendations include withholding GLP-1RAs for a predefined period of time, performing gastric ultrasound to evaluate gastric contents, modifying anesthesia management, particularly with regard to the airway, or canceling the scheduled (elective) surgery or procedure. SGLT-2is are known to increase the risk of euglycemic ketoacidosis. The benefits of both GLP-1RAs and SGLT-2is extend beyond the treatment of diabetes. As a result, perioperative physicians may encounter their use outside of their traditional indications. SGLT-2is are being used extensively to treat heart failure and obesity, for example. There have been other developments as well. For instance, Imeglimin, a variant of metformin available in Japan and India, Icodec, a once-weekly basal insulin formulation, and IcoSema, a once-weekly combination of Icodec plus semaglutide, are all being explored, although in their early stages or facing approval challenges.
- 16 October 2024
- Published by Springer Nature
- p. 1-19
Venous Thromboembolism Prophylaxis in the Surgical Patient
- 16 October 2024
- Published by Springer Nature
- p. 1-19
Venous Thromboembolism Prophylaxis in the Surgical Patient
- 7 March 2024
- Published by Springer Nature
- p. 1-30
The Pulmonary Embolism Response Team and Hospital Relationship
- 7 March 2024
- Published by Springer Nature
- p. 1-30
The Pulmonary Embolism Response Team and Hospital Relationship